纽伦捷

Biotech/Healthcare

NewLegend Bio develops novel gene therapies using its proprietary cell transdifferentiation and gene replacement technologies. The company aims to translate emerging cell transdifferentiation technologies into solutions for unmet clinical needs.

Latest round: Series A (2026)